MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Agenus Company Profile (NASDAQ:AGEN)

Consensus Ratings for Agenus (NASDAQ:AGEN) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.43 (182.19% upside)

Analysts' Ratings History for Agenus (NASDAQ:AGEN)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$17.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$17.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/31/2015OppenheimerReiterated RatingPositive -> Outperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2015Jefferies GroupInitiated CoverageBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015MLV & Co.Reiterated RatingBuy$9.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Agenus (NASDAQ:AGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/21/2016        
4/28/2016Q116($0.23)($0.37)$5.16 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.17)($0.18)$9.39 million$7.64 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315($0.15)($0.16)$7.56 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q215($0.15)($0.44)$5.71 million$6.38 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2015Q115($0.01)($0.28)$11.66 million$3.95 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.16)($0.41)$1.62 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2014Q314($0.15)($0.13)$1.96 million$1.56 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014Q214($0.17)($0.12)$3.07 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.13)($0.01)$0.55 million$0.72 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014Q413($0.24)($0.16)$870.00 million$393.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2013Q313($0.27)($0.24)$736.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013($0.21)($0.40)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012($0.24)($0.23)$0.72 million$1.09 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.05)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Agenus (NASDAQ:AGEN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.18)($0.18)($0.18)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.44)($0.44)($0.44)
Q4 20161($0.47)($0.47)($0.47)
Q1 20171($0.24)($0.24)($0.24)
Q2 20171($0.24)($0.24)($0.24)
Q3 20171($0.25)($0.25)($0.25)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)
Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Agenus (NASDAQ:AGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/9/2016Garo H ArmenCEOBuy100,000$3.18$318,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2016Ozer BaysalInsiderBuy2,250$3.10$6,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Garo H ArmenCEOBuy200,000$4.03$806,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Garo H. ArmenCEOSell219,576$4.59$1,007,853.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Garo H. ArmenCEOSell134,352$4.60$618,019.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Charles Evan BallantyneCFOBuy10,000$5.05$50,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Garo H ArmenCEOBuy100,000$5.03$503,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2015Shahzad MalikDirectorSell1,107,377$7.11$7,873,450.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2015Qvt Associates Gp LlcMajor ShareholderSell2,343,630$5.31$12,444,675.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2014Karen ValentineVPSell2,850$3.50$9,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Agenus (NASDAQ:AGEN)
DateHeadline
06/29/16 02:19 PMAgenus Inc. (AGEN) Jumps 6.89% on June 28 - Equities.com
06/28/16 07:43 PMDoes Agenus Inc Have Any Gas After Today's Huge Increase? - Engelwood Daily
06/28/16 02:34 PMStock Higher in Trade: Agenus Inc. (NASDAQ:AGEN) - Telanagana Press
06/28/16 07:07 AMAgenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : June 28, 2016 -
06/27/16 10:25 AMWhy Agenus' Stock Has Stumbled in 2016 - Agenus has been hurt by the widespread downturn among clinical-stage biotechs this year.
06/27/16 07:07 AMHow Many Agenus Inc (NASDAQ:AGEN)'s Analysts Are Bullish? - Engelwood Daily
06/24/16 10:04 AMAgenus begins patient dosing in phase 1/2 study of anti-GITR agonist antibody INCAGN1876 in patients with solid tumors
06/24/16 07:06 AMBetter Buy: Agenus Inc. vs. bluebird bio -
06/23/16 03:49 PMBRIEF-Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
06/22/16 02:22 PMBRIEF-Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody - Reuters
06/21/16 02:20 PMAgenus Inc. (NasdaqCM:AGEN) Stock Momentum at Critical Inflection Point - CML News
06/21/16 07:08 AMAgenus Inc. (AGEN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/21/16 07:08 AMRecently Issued Stock Ratings For Agenus Inc. (AGEN) - Fiscal Standard
06/20/16 02:35 PMAgenus Charts Shows Upside Potential -
06/20/16 08:52 AMTop News: Agenus Inc. (NASDAQ:AGEN), Milestone Scientific Inc. (NYSEMKT:MLSS), Synchronoss Technologies, Inc ... - KC Register
06/17/16 02:21 PMForm 4 AGENUS INC For: Jun 15 Filed by: JORDAN WADIH - StreetInsider.com
06/17/16 10:16 AMForm 4 AGENUS INC For: Jun 14 Filed by: Ballantyne Charles Evan - StreetInsider.com
06/16/16 07:01 AMAGENUS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits -
06/15/16 07:26 PMAgenus Inc.: Agenus to Present at the 2016 JMP Securities Life Sciences Conference - The Wall Street Transcript
06/15/16 02:24 PMAgenus Inc. (NASDAQ:AGEN) To Report June 2016 Results - iStreetWire
06/15/16 08:09 AMAgenus to Present at the 2016 JMP Securities Life Sciences Conference - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today ...
06/14/16 07:10 AMStocks Showing Momentum: Agenus Inc. (NASDAQ:AGEN), Exact Sciences Corporation (NASDAQ:EXAS) - Beacon Chronicle
06/13/16 10:29 AMNovavax, Inc. (NASDAQ:NVAX) Median One Year Price Target Is $14
06/12/16 01:00 PMPut Agenus, Progenics on Your Small-Cap List -
06/11/16 02:22 PMAnalyst Rating Trends to Observe: Agenus Inc. (NASDAQ:AGEN) , BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Street Updates
06/11/16 02:22 PMAnalyst Rating Trends to Observe: Agenus Inc. (NASDAQ:AGEN) , BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Street Updates
06/09/16 08:14 PMAgenus Inc.: Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck - The Wall Street Transcript
06/08/16 08:08 AMAgenus to Webcast Annual Meeting of Stockholders - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites ...
06/07/16 07:56 PMLatest report on Agenus, Inc. - product pipeline review - 2016 just published - WhaTech
06/07/16 10:45 AMInvestors Focused Movers: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Agenus Inc. (NASDAQ:AGEN) - Street Updates
06/07/16 10:45 AMAgenus, Inc. Pipeline Review, Market Share, Strategy, Size and Forecast 2016 – 2020 - Medgadget.com (blog)
06/06/16 07:58 PMAgenus, Inc. – Product Pipeline Review – 2016 - Medgadget.com (blog)
06/06/16 02:22 PMTwo Movers within Investors Observation: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) , Agenus Inc. (NASDAQ ... - Street Updates
06/04/16 07:40 PMEarnings Expectations Overview: Agenus Inc. (NASDAQ:AGEN), F.N.B. Corporation (NYSE:FNB) - Beacon Chronicle
06/03/16 10:49 AMHealthcare Stock's Latest Update : Medtronic plc (NYSE:MDT) , Agenus Inc. (NASDAQ:AGEN) - Is stories
06/03/16 10:49 AMAgenus Inc. (AGEN) Jumps 6.64% on June 02 - Equities.com
06/02/16 02:24 PMWorthy Stocks to Watch: Agenus Inc (NASDAQ:AGEN), Lpath, Inc. (NASDAQ:LPTN), Neovasc Inc (US) (NASDAQ:NVCN) - The Point Review - Worthy Stocks to Watch: Agenus Inc (NASDAQ:AGEN), Lpath, Inc. (NASDAQ:LPTN), Neovasc Inc (US) (NASDAQ:NVCN)The Point ReviewShares of Agenus Inc (NASDAQ:AGEN) flew 10.42% to $4.66 at 11:50 AM EDT. The stock attained the volume of 1.02 Million shares recently versus average trading volume of 1.03 Million shares. If we take a look on its volatility, 4.88 percent was seen in a ...Agenus Inc (NASDAQ:AGEN)'s Company Shares Increased 20.57% After High VolatilityFranklin IndependentAnalyst Coverage: Agenus Inc. (AGEN)Risers & FallersTop Stock in Session: Agenus Inc. (NASDAQ:AGEN)The PostBusiness Wire (press release)all 4 news articles »
06/02/16 08:15 AMAgenus to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today ...
06/01/16 02:23 PMWill You Buy These Stocks? - Agenus Inc. (NASDAQ:AGEN), Linear Technology Corporation (NASDAQ:LLTC) - Beacon Chronicle - Beacon ChronicleWill You Buy These Stocks? - Agenus Inc. (NASDAQ:AGEN), Linear Technology Corporation (NASDAQ:LLTC)Beacon ChronicleLast Trade: The Company closed its last session at $47.32 with the gain of 0.32%. The market capitalization of the company is $11.29 Billion, with the average Volume of 2.32 Million. The stock currently has its 52-Week High range of $47.54 and 52-week ...and more »
06/01/16 10:45 AMBuy, Sell Or Hold Rating For Agenus Inc. (AGEN)? - Share Trading News - Buy, Sell Or Hold Rating For Agenus Inc. (AGEN)?Share Trading News03/11/2016 – Agenus Inc. was upgraded to “buy” by analysts at Maxim Group. They now have a USD 7 price target on the stock. 03/09/2016 – Agenus Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 15 price target on ...The Statistics Don't Lie: Agenus Inc. (NASDAQ:AGEN) Earnings PreviewiStreetWireall 2 news articles »
06/01/16 10:45 AMAgenus Inc. (NASDAQ:AGEN) Quarterly EPS Estimate At $-0.35 - Investor Newswire - Agenus Inc. (NASDAQ:AGEN) Quarterly EPS Estimate At $-0.35Investor NewswireFirst Call stated that Agenus Inc. (NASDAQ:AGEN) can touch $10.40 in coming one year. For the next quarter, the per-share earnings target is $-0.35 and for ongoing fiscal at $-1.41. EPS target for next year is $-1.48 versus the mean EPS of $-1.22 last ...and more »
05/31/16 08:23 AMStock Review and Earnings Check on Agenus Inc. (NASDAQ:AGEN) - HNN - Stock Review and Earnings Check on Agenus Inc. (NASDAQ:AGEN)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Agenus Inc. (NASDAQ:AGEN) to ...and more »
05/31/16 08:23 AMBiotech Movers: AbbVie Inc. (NYSE:ABBV) , Agenus Inc. (NASDAQ:AGEN) - Is stories - Is storiesBiotech Movers: AbbVie Inc. (NYSE:ABBV) , Agenus Inc. (NASDAQ:AGEN)Is storiesAbbVie Inc. (NYSE:ABBV) increased +1.31% to $62.71 while traded 5.77 million shares on 5/27/2016. The stock price negotiated for value between $61.90 to $63.20 in recent trading session. During the past 52 weeks, the stock's price witnessed a minimum ...and more »
05/31/16 08:15 AMEarly Morning Technical Highlights on Biotech Stocks -
05/30/16 10:36 AMHC Stocks News Ring: Geron Corporation (NASDAQ:GERN), Agenus Inc (NASDAQ:AGEN) - share market updates (press release) - share market updates (press release)HC Stocks News Ring: Geron Corporation (NASDAQ:GERN), Agenus Inc (NASDAQ:AGEN)share market updates (press release)Shares of Geron Corporation (NASDAQ:GERN) ended Friday session in green amid volatile trading. The shares closed up +0.04 points or 1.42% at $2.85 with 1.07 million shares getting traded. Post opening the session at $2.82, the shares hit an intraday ...Are Analysts Bearish Agenus Inc (NASDAQ:AGEN) After Last Week?HNNall 3 news articles »
05/30/16 07:41 AM2 Biotech Stocks Under $5 With Jaw-Dropping Growth Potential - Agenus and Amarin's share prices could soar over the next year. Are these two speculative biotechs worth the risk?
05/29/16 11:57 PMAgenus Inc. (NASDAQ:AGEN) Quarterly EPS From Continuing Operations Stands At $-0.3666 - RealistInvestor.com - Agenus Inc. (NASDAQ:AGEN) Quarterly EPS From Continuing Operations Stands At $-0.3666RealistInvestor.comFor the year ended 2016-03-31 Agenus Inc. (NASDAQ:AGEN) basic consolidated EPS reported was $-1.1236. For the quarter ended 2016-03-31, it came at $-1.1236. EPS is a part of a firm's earnings that is owed to each outstanding stock. Calculated by ...
05/29/16 06:49 PMAre Analysts Bearish Agenus Inc (NASDAQ:AGEN) After Last Week? - HNN - Are Analysts Bearish Agenus Inc (NASDAQ:AGEN) After Last Week?HNNOut of 5 analysts covering Agenus (NASDAQ:AGEN), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Agenus has been the topic of 5 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Below is a list of ...
05/29/16 06:49 PMAgenus Inc. (NASDAQ:AGEN) Impact Score At 94 - Investor Newswire - Agenus Inc. (NASDAQ:AGEN) Impact Score At 94Investor NewswireAlpha One explored various online articles released on Agenus Inc. (NASDAQ:AGEN), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued on ...and more »
05/28/16 06:52 PMAgenus Inc's Trend Up, Especially After Today's Strong Session - HNN - Agenus Inc's Trend Up, Especially After Today's Strong SessionHNNThe stock of Agenus Inc (NASDAQ:AGEN) is a huge mover today! The stock increased 3.85% or $0.15 during the last trading session, hitting $4.05. It is down 19.48% since October 22, 2015 and is downtrending. It has underperformed by 23.01% the S&P500.Agenus Inc. (NASDAQ:AGEN): Analysts Quick Take on EarningsNews Tribuneall 2 news articles »
About Agenus

Agenus logoAgenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AGEN
  • CUSIP: 00847G70
Key Metrics:
  • Previous Close: $3.97
  • 50 Day Moving Average: $3.93
  • 200 Day Moving Average: $3.78
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $350.13M
  • Current Quarter EPS Consensus Estimate: $-1.41 EPS
Additional Links:
Agenus (NASDAQ:AGEN) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha